A Genetic Lottery
— Rebecca Field

The CHDI Foundation, a privately-funded nonprofit research organization dedicated to fighting Huntington’s disease, has awarded a research grant to a team of scientists from the University of Rochester Medical Center (URMC) to study the…

Abnormal energy production may contribute to the progression of Huntington’s disease, according to a new study. The study, entitled “The Phasor-FLIM Fingerprints Reveal Shifts From OXPHOS To Enhanced Glycolysis In Huntington Disease,” was recently published…

Progressive neurological diseases, such as Huntington’s disease, are associated with pathological changes in the retina and the brain. According to Henri Leinonen from the University of Eastern Finland (UEF) and colleagues, such disorders might…

A survey of 1,700 Huntington’s disease patients that questioned issues such as symptoms, treatment, and disease management, revealed some surprising facts that can impact how physicians and researchers view and treat the condition. Particularly,…

A recent review summarizes the scientific literature on behavioral and psychiatric symptoms of Huntington’s disease, noting that plenty of research is still needed to better understand and treat such symptoms, which traditionally have taken…

Researchers have developed a new gene-editing tool that may improve the precision of future gene therapy efforts in Huntington’s disease, as well as numerous other genetic conditions. The study, “A chemical-inducible…

Teva Pharmaceutical presented encouraging top-line data from PRIDE-HD, a Phase 2 clinical trial evaluating the impact of pridopidine, an oral medication, on motor impairment in patients with Huntington’s disease (HD). Teva is now…

Mice models of Huntington’s disease, infected with a parasite commonly found in humans, react in a different way to the infection than normal mice, researchers have revealed. The study suggests that infection and immune…

Attempts to block the activity of the mutant huntingtin gene, which causes Huntington’s disease, may have taken a big step forward. Scientists report they successfully silenced the gene for six months after a single injection…

Voyager Therapeutics has partnered with the CHDI Foundation to advance its VY-HTT01 gene-silencing therapy for Huntington’s disease (HD). The research alliance with CHDI builds upon an earlier partnership between CHDI and Sanofi Genzyme…

Using a new Huntington’s disease model featuring two types of disease affected neurons grown together in the lab, researchers showed that introducing a specific protein part reduced mutant huntingtin, as well as other molecular…

Inflammatory processes in both the brain and the rest of the body are likely an integral part of Huntington’s disease, according to a review of published data on the topic. The report,…